The Hepatitis B Vaccine Market Size Was Valued At USD 7.53 Billion In 2021. The Market Is Projected To Grow From USD 7.80 Billion In 2022 To USD 10.62 Billion By 2030, Exhibiting a CAGR Of 4.5% During The Forecast Period. Global Hepatitis B Vaccine Market Reports give a Key study on the industry status of the Hepatitis B Vaccine Industry Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across the globe. The research report also covers the Market Size, Price, Sales, Revenue, Market share, Gross Margin, growth rate, and cost structure. The report aims to give an additional sample of the latest scenario, economic slowdown, and Covid-19 impact on overall Industry.
Get Sample PDF Brochure with Table of Contents and Important Figures @
https://www.contrivedatuminsights.com/request-sample/248514
The COVID-19 pandemic has been shocking and has never happened before. Demand for the hepatitis B vaccine is lower than expected in all areas compared to levels before the pandemic. According to our research, the global market for hepatitis B vaccines will be 11.0% smaller in 2020 than it was in 2019.
Hepatitis B Virus (HBV) is a major cause of cirrhosis, chronic hepatitis, and hepatocellular cancer. It is a serious threat to people’s health all over the world. There have been a lot more cases of hepatitis B because infected mothers pass it on to their babies at birth or because babies come in contact with an infected person’s body fluids (such as blood or saliva).
Competitive Landscape and Global Market Share Analysis:
GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China), Others
Market Segmentation:
By Type:
- Single Antigen
- Combination
- Others
By Distribution Channel:
- Hospitals
- Government Suppliers
- Others
The report on the Hepatitis B Vaccine market covers the following region (country) analysis:
- North America (U.S., Canada)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
- South America (Mexico, Brazil, Argentina, Columbia, Rest of South America)
- Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)
Regional Insights:
The North American market was worth USD 2.60 billion in 2021, and it is expected to stay the biggest market in the world for the rest of the forecast period. Hepatitis B diseases are becoming more common, and national health organisations have taken steps to prevent them, test for them, and lower the number of people who die from them. North America, which has the largest share of the world market, has been most affected by this. North America’s market is also growing because more companies are teaming up and getting approval for more combination vaccines. Many people in the area use these vaccines.
Sanofi Pasteur and Merck & Co., Inc. worked together to bring Vaxelis to the U.S. in June 2021. It was the first vaccine that protects children and babies from diseases like diphtheria, tetanus, polio, Haemophilus influenzae type B (Hib), and hepatitis B.
Europe is the second most important area in terms of sales and market share. European government officials set up a number of regional action plans to protect more newborn babies from getting hepatitis B. This is why the European market held a large share. For example, the World Health Organization says that by December 2019, 50 out of 53 European countries will offer routine hepatitis B vaccinations to all infants and children ages 1–12. This includes 23 countries that give all newborns a dose of hepatitis B at birth.
Asia-share The growing number of people with hepatitis B disease is driving Pacific’s share of the hepatitis B vaccine market. At the same time, companies that make vaccines are trying to raise money and work together to make new hepatitis B vaccines, which are expected to help the region grow at the highest CAGR over the next few years. In April 2022, for example, Shionogi & Co., Ltd., a Japanese pharmaceutical company that focuses on research, worked with NEC Corporation to study and make a new hepatitis B vaccine. The goal of the collaboration is to find a cure for hepatitis B and meet all of the disease’s medical needs.
On the other hand, the Rest of the World (RoW) market, which includes Latin America and the Middle East, is likely to grow more slowly. Because more people in the area have hepatitis B and different strategic frameworks are being used, the market is growing faster there.
Following are the major TOC of the Hepatitis B Vaccine Market:
Chapter 1: Hepatitis B Vaccine Market Overview
Chapter 2: Global Economic Impact on Industry
Chapter 3: Global Hepatitis B Vaccine Market Competition by Manufacturers
Chapter 4: Global Production, Profits (Value) by Region
Chapter 5: Global Supply (Production), Import, Export, Consumption, by Regions
Chapter 6: Global Price Trend by Type, Revenue (Value), Production
Chapter 7: Manufacturing Cost Analysis
Chapter 8: Global Market Analysis by Application
Chapter 9: Industrial Chain and Downstream Buyers, Sourcing Strategy
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Global Hepatitis B Vaccine Market Forecast
Buy Now:
https://www.contrivedatuminsights.com/buy/248514
Key Reasons to Purchase Hepatitis B Vaccine Market report:
The report provides a thorough examination of the manufacturing methods, as well as ideas to reduce development risk, major market growth challenges and strategic inputs to overcome the market threats.
In-depth market analysis and an overview of the global Hepatitis B Vaccine Market trend and commercial landscape are included in the report. In addition, the report discusses the effect of COVID-19 on the market.
Reader can acquire a better interpretation of the Hepatitis B Vaccine Market forecast’s future view and opportunities from the report.
The report contains an analysis of recent developments as well as profiles of important market leaders and key players.
To gain an understanding of the market strategies by the leading market players in the Hepatitis B Vaccine
The report analyses the most important driving and restraining factors in the industry, as well as their impact on global market growth.
About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials in various sectors including investment, information technology, telecommunications, consumer technology, and manufacturing markets. CDI helps investment communities, business executives and IT professionals make accurate, statistically-based decisions on technology purchases and promote strong growth tactics to maintain market competitiveness. Composed of a team of more than 100 analysts and a cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and national experience.
Contact Us:
Anna B. (Head Of sales) | Contrive Datum Insights
Contact No- +91 9834816757 / +1 2152974078
[email protected]